DGS Capital Management LLC Makes New Investment in InMode Ltd. (NASDAQ:INMD)

DGS Capital Management LLC bought a new stake in shares of InMode Ltd. (NASDAQ:INMD) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 10,756 shares of the healthcare company’s stock, valued at approximately $182,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Asset Dedication LLC acquired a new stake in InMode in the second quarter valued at $33,000. nVerses Capital LLC acquired a new stake in shares of InMode in the 2nd quarter valued at about $42,000. Nisa Investment Advisors LLC lifted its position in shares of InMode by 314.7% during the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after purchasing an additional 2,694 shares during the last quarter. Quarry LP grew its stake in InMode by 154.3% in the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after purchasing an additional 2,294 shares in the last quarter. Finally, National Bank of Canada FI increased its holdings in InMode by 40.7% in the second quarter. National Bank of Canada FI now owns 9,406 shares of the healthcare company’s stock valued at $168,000 after buying an additional 2,720 shares during the last quarter. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Trading Down 1.3 %

Shares of InMode stock opened at $18.26 on Friday. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of 9.87 and a beta of 2.07. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80. The business’s 50 day simple moving average is $18.08 and its 200-day simple moving average is $17.50.

Wall Street Analysts Forecast Growth

A number of research firms have commented on INMD. BTIG Research assumed coverage on InMode in a report on Thursday, October 17th. They set a “buy” rating and a $25.00 target price on the stock. Barclays reduced their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Monday, October 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $22.60.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.